Kyle Robert A, Treon Steven P, Alexanian Raymond, Barlogie Bart, Björkholm Magnus, Dhodapkar Madhav, Lister T Andrew, Merlini Giampaolo, Morel Pierre, Stone Marvin, Branagan Andrew R, Leblond Véronique
Mayo Clinic, Rochester, MN, USA.
Semin Oncol. 2003 Apr;30(2):116-20. doi: 10.1053/sonc.2003.50038.
This presentation represents consensus recommendations on prognostic markers and criteria to initiate therapy in patients with Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the Second International Workshop held in Athens, Greece during September 2002. The panel recommended that initiation of therapy should not be based on the IgM level per se since this may not correlate with the clinical manifestations of WM. The consensus panel agreed that initiation of therapy was appropriate for patients with constitutional symptoms such as recurrent fever, night sweats, fatigue due to anemia, or weight loss. The presence of progressive, symptomatic lymphadenopathy or splenomegaly provide additional reasons to begin therapy. The presence of anemia with a hemoglobin value of <or= 10 g/dL or a platelet count < 100 x 10(9)/L due to marrow infiltration also justifies treatment. Certain complications such as hyperviscosity syndrome, symptomatic sensorimotor peripheral neuropathy, systemic amyloidosis, renal insufficiency, or symptomatic cryoglobulinemia may also be indications for therapy. Recommendations for follow-up of watch-and-wait patients are that those with monoclonal gammopathy of undetermined significance (MGUS) should have serum protein electrophoresis repeated each year. Patients with asymptomatic (smoldering) macroglobulinemia should be evaluated every 6 months. Regarding prognostic markers, hemoglobin and beta(2)-microglobulin levels at diagnosis are important prognostic markers in WM: they influence the timing of treatment and survival. Age is a consistently important prognostic factor for survival. However, the panel felt that current data are inadequate to support the use of any prognostic marker to select the timing and type of therapy, and called for studies on the application of prognostic markers in WM.
本报告代表了关于华氏巨球蛋白血症(WM)患者预后标志物及启动治疗标准的共识性建议,这些建议是与2002年9月在希腊雅典举行的第二届国际研讨会共同制定的。专家小组建议,治疗的启动不应仅基于IgM水平本身,因为这可能与WM的临床表现不相关。共识小组一致认为,对于有诸如反复发热、盗汗、贫血所致疲劳或体重减轻等全身症状的患者,启动治疗是合适的。进行性、有症状的淋巴结病或脾肿大的存在为开始治疗提供了额外的理由。由于骨髓浸润导致血红蛋白值≤10 g/dL或血小板计数<100×10⁹/L的贫血的存在也证明需要治疗。某些并发症,如高粘滞综合征、有症状的感觉运动性周围神经病、系统性淀粉样变性、肾功能不全或有症状的冷球蛋白血症,也可能是治疗的指征。对于观察等待患者的随访建议是,意义未明的单克隆丙种球蛋白病(MGUS)患者应每年重复进行血清蛋白电泳。无症状(冒烟型)巨球蛋白血症患者应每6个月评估一次。关于预后标志物,诊断时的血红蛋白和β₂微球蛋白水平是WM重要的预后标志物:它们影响治疗时机和生存。年龄是生存的一个始终重要的预后因素。然而,专家小组认为目前的数据不足以支持使用任何预后标志物来选择治疗的时机和类型,并呼吁开展关于预后标志物在WM中应用的研究。